Page 48 - IMO-2-3

Innovative Medicines & Omics Tyrosine kinases: Structure, mechanism, and therapeutics

anti-HER2 therapies in breast cancer. J Natl Cancer Inst. HER2 dimerization inhibiting monoclonal antibody, in
2007;99(8):628-638. combination with trastuzumab (T) in patients (pts) with
HER2-positive metastatic breast cancer (MBC) which
doi: 10.1093/jnci/djk134
has progressed during treatment with T. J Clin Oncol.
170. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus 2007;25(18_suppl):1004.
capecitabine for HER2-positive advanced breast cancer. doi: 10.1200/jco.2007.25.18_suppl.1004
N Engl J Med. 2006;355(26):2733-2743.
180. Baselga J, Swain SM. Novel anticancer targets: Revisiting
doi: 10.1056/NEJMoa064320
ERBB2 and discovering ERBB3. Nat Rev Cancer.
171. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and 2009;9(7):463-475.
chemotherapy as initial treatment for metastatic colorectal doi: 10.1038/nrc2656
cancer. N Engl J Med. 2009;360(14):1408-1417.
181. Xiao T, Ali S, Mata D, Lohmann AE, Blanchette PS. Antibody-
doi: 10.1056/NEJMoa0805019
drug conjugates in breast cancer: Ascent to destiny and
172. Cunningham D, Humblet Y, Siena S, et al. Cetuximab beyond-a 2023 review. Curr Oncol. 2023;30(7):6447-6461.
monotherapy and cetuximab plus irinotecan in irinotecan- doi: 10.3390/curroncol30070474
refractory metastatic colorectal cancer. N Engl J Med.
2004;351(4):337-345. 182. Zhou S, Liu M, Ren F, Meng X, Yu J. The landscape of
bispecific T cell engager in cancer treatment. Biomark Res.
doi: 10.1056/NEJMoa033025 2021;9(1):38.
173. Van Emburgh BO, Sartore-Bianchi A, Di Nicolantonio F, doi: 10.1186/s40364-021-00294-9
Siena S, Bardelli A. Acquired resistance to EGFR-
targeted therapies in colorectal cancer. Mol Oncol. 183. Desmonts G, Daffos F, Forestier F, Capella-Pavlovsky M,
2014;8(6):1084-1094. Thulliez P, Chartier M. Prenatal diagnosis of congenital
toxoplasmosis. Lancet. 1985;1(8427):500-504.
doi: 10.1016/j.molonc.2014.05.003
doi: 10.1016/s0140-6736(85)92096-3
174. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras
mutations and benefit from cetuximab in advanced 184. Masuda H, Zhang D, Bartholomeusz C, Doihara H,
colorectal cancer. N Engl J Med. 2008;359(17):1757-1765. Hortobagyi GN, Ueno NT. Role of epidermal growth
factor receptor in breast cancer. Breast Cancer Res Treat.
doi: 10.1056/NEJMoa0804385 2012;136(2):331-345.
175. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. doi: 10.1007/s10549-012-2289-9
Oncogenic activation of the RAS/RAF signaling pathway
impairs the response of metastatic colorectal cancers to 185. Viale G, Rotmensz N, Maisonneuve P, et al. Invasive ductal
anti-epidermal growth factor receptor antibody therapies. carcinoma of the breast with the “triple-negative” phenotype:
Cancer Res. 2007;67(6):2643-2648. Prognostic implications of EGFR immunoreactivity. Breast
Cancer Res Treat. 2009;116(2):317-328.
doi: 10.1158/0008-5472.Can-06-4158
doi: 10.1007/s10549-008-0206-z
176. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is
required for panitumumab efficacy in patients with metastatic 186. Finn RS. Targeting Src in breast cancer. Ann Oncol.
colorectal cancer. J Clin Oncol. 2008;26(10):1626-1634. 2008;19(8):1379-1386.
doi: 10.1200/jco.2007.14.7116 doi: 10.1093/annonc/mdn291
177. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, 187. Zheng R, Gagan JR, Botten GA, et al. Genomic landscape
BRAF, NRAS, and PIK3CA mutations on the efficacy of of mixed phenotype acute leukemia associated with
cetuximab plus chemotherapy in chemotherapy-refractory immunophenotypic lineage predominance: Impact on
metastatic colorectal cancer: A retrospective consortium diagnosis and treatment. Eur J Haematol. 2025;114:1041-1051.
analysis. Lancet Oncol. 2010;11(8):753-762. doi: 10.1111/ejh.14414
doi: 10.1016/s1470-2045(10)70130-3 188. Irby RB, Yeatman TJ. Role of Src expression and activation
178. Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA in human cancer. Oncogene. 2000;19(49):5636-5642.
mutations in colorectal cancer are associated with clinical doi: 10.1038/sj.onc.1203912
resistance to EGFR-targeted monoclonal antibodies. Cancer 189. Zhang J, Kalyankrishna S, Wislez M, et al. SRC-family
Res. 2009;69(5):1851-1857.
kinases are activated in non-small cell lung cancer and
doi: 10.1158/0008-5472.Can-08-2466 promote the survival of epidermal growth factor receptor-
dependent cell lines. Am J Pathol. 2007;170(1):366-376.
179. Baselga J, Cameron D, Miles D, et al. Objective response
rate in a phase II multicenter trial of pertuzumab (P), a doi: 10.2353/ajpath.2007.060706

Volume 2 Issue 3 (2025) 42 doi: 10.36922/IMO025200022